Clinical Trial: Atorvastatin Therapy in the Treatment of Dyslipidemia in Children With Steroid Sensitive Nephrotic Syndrome

U.S., March 28 -- ClinicalTrials.gov registry received information related to the study (NCT07497776) titled 'Atorvastatin Therapy in the Treatment of Dyslipidemia in Children With Steroid Sensitive Nephrotic Syndrome' on March 13.

Brief Summary: To evaluate the effectiveness and safety of Atorvastatin therapy in children with dyslipidemia in steroid sensitive nephrotic syndrome.

Study Start Date: Jan. 27, 2024

Study Type: INTERVENTIONAL

Condition: Dyslipidaemia

Intervention: DRUG: Atorvastatin

Atorvastatin 10 mg nightly dose

Recruitment Status: COMPLETED

Sponsor: National Institute of Kidney Disease and Urology (NIKDU)

Information provided by (Responsible Party): Saieef Zaman, National Institute of Kidney Disease and Urology (NI...